| Literature DB >> 36158568 |
Antonio Noto1, Cristina Piras1, Luigi Atzori1, Michele Mussap2, Andrea Albera3, Roberto Albera3, Augusto Pietro Casani4, Silvia Capobianco4, Vassilios Fanos1.
Abstract
Otorhinolaryngology (Ear, Nose and Throat-ENT) focuses on inflammatory, immunological, infectious, and neoplastic disorders of the head and neck and on their medical and surgical therapy. The fields of interest of this discipline are the ear, the nose and its paranasal sinuses, the oral cavity, the pharynx, the larynx, and the neck. Besides surgery, there are many other diagnostic aspects of ENT such as audiology and Vestibology, laryngology, phoniatrics, and rhinology. A new advanced technology, named metabolomics, is significantly impacting the field of ENT. All the "omics" sciences, such as genomics, transcriptomics, and proteomics, converge at the level of metabolomics, which is considered the integration of all "omics." Its application will change the way several of ENT disorders are diagnosed and treated. This review highlights the power of metabolomics, including its pitfalls and promise, and several of its most relevant applications in ENT to provide a basic understanding of the metabolites associated with these districts. In particular, the attention has been focused on different heterogeneous diseases, from head and neck cancer to allergic rhinitis, hearing loss, obstructive sleep apnea, noise trauma, sinusitis, and Meniere's disease. In conclusion, metabolomics study indicates a "fil rouge" that links these pathologies to improve three aspects of patient care: diagnostics, prognostics, and therapeutics, which in one word is defined as precision medicine.Entities:
Keywords: Otorhinolaryngology; hearing loss; metabolites; metabolomics; precision medicine; sleep apnea; vertigo
Year: 2022 PMID: 36158568 PMCID: PMC9493185 DOI: 10.3389/fmolb.2022.934311
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
Selected characteristics of reviewed studies on ORL.
| Author | Years | Sample size | Biofluid | Technique | Biomarkers Candidates | Results | Comments |
|---|---|---|---|---|---|---|---|
| Increase (↑) or decrease (↓) biomarker concentration compared to the control group | |||||||
| Head and neck cancers | |||||||
| Almadori et al. | 2007 | 127 subjects: 50 patients with oral and pharyngeal squamous cell carcinomas and 77 healthy controls | Saliva | HPLC-MS | Glutathione | Glutathione ↑ | |
| Sugimoto et al. | 2010 | 158 subjects: 69 oral cancer patients and 89 healthy controls | Saliva | CE-TOF-MS | Betaine; Isoleucine; Leucine; Phenylalanine; Tyrosine; Valine; Choline; Carnitine; Glycerophosphocholine; Cadaverine; Putrescine; Hypoxanthine; Ethanolamine; Trimethylamine; Tryptophan; Valine; Glutamic acid; Glutamine; Aspartate; Taurine; Lysine; Pyrroline hydroxycarboxylic acid; Pipecolic acid; Piperidine; Serine; β-alanine; Histidine | Isoleucine ↑ | |
| Leucine ↑ Taurine ↑ | |||||||
| Valine ↑ Tryptophan ↑ | |||||||
| Putrescine ↑ Alanine ↑ | |||||||
| Pipecolic acid ↑ | |||||||
| Choline ↑ | |||||||
| Glycerophosphocholine ↑ | |||||||
| Histidine ↑ Carnitine ↑ | |||||||
| Threonine ↑ Glutamate ↑ | |||||||
| Tiziani et al. | 2009 | 15 subjects with oral cancer and 10 controls | Serum | 1H-NMR | Valine, Ethanol, Lactate, Alanine, Acetate, Citrate, Phenylalanine, Tyrosine, Methanol, Formaldehyde; Formic acid; Glucose; Pyruvate; Acetone, Acetoacetate; 3-hydroxybutyrate; 2-hydroxybutyrate; Choline; Betaine; Dimethylglycine; Sarcosine; Asparagine; Ornithine | Valine ↓ Ethanol ↓ | The metabolomics profile of patients with oral cancer at the different stages of the disease was also evaluated |
| Lactate ↓ Alanine ↓ Acetate ↓ Citrate ↓ Phenylalanine ↓ | |||||||
| Tyrosine ↓ Methanol ↓ Formaldehyde ↓ Formic acid ↓ Glucose ↑ | |||||||
| Pyruvate ↑ Acetone ↑ Acetoacetate ↑ 3-hydroxybutyrate ↑ | |||||||
| 2-hydroxybutyrate↑ Choline ↑ Betaine ↑ Dimethylglycine ↑ Sarcosine ↑ Asparagine ↑ Ornithine ↑ | |||||||
| Yonezawa et al. | 2013 | Serum and Tissue | GC-MS | Glucose; Ribulose; Methionine; Ketoisoleucine; Histidine, Aspartic acid, Glutamic acid, Asparagine, Lysine, Serine, Methionine; Alanine | In serum: | ||
| Glucose ↑ Ribulose ↑ | |||||||
| Methionine ↓ Ketoisoleucine ↓ | |||||||
| In tissue: | |||||||
| Histidine ↑ | |||||||
| Aspartic acid ↑ | |||||||
| Glutamic acid ↑ Asparagine ↑ Lysine ↑ Serine ↑ Methionine ↑ Alanine ↑ Glucose ↓ | |||||||
| Allergic rinitis | |||||||
| Ma et al. | 2020 | 28 allergic rhinitis patients and 28 healthy controls | Serum | UPLC-QTOF-MS | Bilirubin; Hypoxanthine; 15(S)-HETE*; Hexadecenoic acid; Urate; **13(S)-HPODE; Leukotriene D4; Stercobilinogen; N-succinyl-diaminopimelic acid; Chlorophyll b | Bilirubin ↑ |
|
| Hypoxanthine ↑ | |||||||
| 15(S)-HETE ↑ Hexadecenoic acid ↑ | |||||||
| Urate ↑ | The metabolites were mainly involved in pathways of porphyrin and chlorophyll metabolism, arachidonic acid metabolism, and purine metabolism | ||||||
| Leukotriene D4 ↓ Stercobilinogen ↓ | |||||||
| N-succinyl-diaminopimelic acid ↓ Chlorophyll b ↓ | |||||||
| Zheng et al. | 2021 | 73 patients with allergic rhinitis: 35 and 38 patients with single or double-mite subcutaneous immunotherapy respectively. | Serum | UPLC-QTOF-MS | *HETE; **HEPE; | In SM-SCIT and DM-SCIT patients: |
|
| ***HODE; | *HETE ↓ **HEPE ↓ |
| |||||
| 11(S)-HETE; 8(S)-HETE; 5(S)-HEPE; Arachidonic acid; Eicosapentaenoic acid (EPA); 9(S)- hydroperoxylinoleic acid (HPODE) | ***HODE ↓ |
| |||||
| In DM-SCIT patients: | |||||||
| 11(S)-HETE ↓ | |||||||
| 8(S)-HETE ↓ 5(S)-HEPE↓ Arachidonic acid↓ Eicosapentaenoic acid (EPA) ↓ | |||||||
| In SM-SCIT patients: | |||||||
| HPODE ↑ | |||||||
| Yuan et al. | 2022 | 28 patients with allergic rhinitis | Serum | UPLC-QTOF-MS | 26 altered metabolites between: | Prostaglandin E2 ↑ Prostaglandin H2 ↑ Prostaglandin D2 ↑ Thromboxane A2 ↑ 20-Hydroxy-leukotriene B4 ↑ Linoleic acid ↑ 9,10-Epoxyoctadecenoic acid ↑ 12,13-EpOME ↑ Paraxanthine ↑ Theobromine ↑ | The metabolites were mainly involved in linoleic acid metabolism, arachidonic acid metabolism and caffeine metabolism |
| 15 healthy individuals | Prostaglandin E2; Prostaglandin H2; Prostaglandin D2; Thromboxane A2; 20-Hydroxy-leukotriene B4; Linoleic acid; 9,10-Epoxyoctadecenoic acid; 12,13-EpOME; Paraxanthine; Theobromine; | ||||||
| Hearing loss | |||||||
| Trinh et al. | 2019 | 19 patients affected by sensorineural hearing loss: | Perilyph fluid | LC-MS/MS | N-acetylneuraminate, Glutaric acid, l-cystine, 2-methylpropanoate, Butanoate, Xanthine, l-histidine, S-lactate, 4-hydroxy-l-proline, Serotonin, 2-deoxy-D-Glucose, N-acetyl-l-Alanine; l-proline; Taurine | Patients >12 years: N-acetylneuraminate ↑ | |
| 10 patients ≤12 years | |||||||
| 9 patients >12 years | |||||||
| Meniere’s disease | |||||||
| Di Bernardino F. et al. | 2018 | 26 patients with definite unilateral MD: 14 patients symptomatic and 12 asymptomatic 20 healthy volunteers | Urine | Double sugar test and fecal calprotectin | Lactulose and mannitol absorption | In the symptomatic MD symptomatic: Lactulose and mannitol absorption ↑ | |
| Fecal calprotectin (FC) | FC ↑ | ||||||
| Obstructive sleep apnea (OSA) | |||||||
| Xu et al. | 2016 | 60 OSA patients | Urine | UPLC-QTOF-MS coupled with GC-TOF-MS | 3-hydroxybutyric acid; 3-methyl-3-hydroxybutyric acid; 4-hydroxypentenoic acid; Lactic acid; Myoinositol; 2-Butenedioic acid | OSA patients compared to SS and control groups: | |
| 30 simply snored patients (SS) | 3-hydroxybutyric acid↑ 3-methyl-3-hydroxybutyric acid ↑ 4-hydroxypentenoic acid ↑ | ||||||
| 30 controls | OSA patients compared to control groups: lactic acid ↑ myoinositol ↑ 2-butenedioic acid ↓ | ||||||
| Lebkuchen et al. | 2018 | 37 patients with OSA | Plasma | MALDI-TOF-MS | Glycerophosphoethanolamines (PE-35:1); Lyso-phosphocholines (LPC-27:1); Sphingomyelin (SM-d18:1/12:0); Glutamic acid, Deoxy sugar; Arachidonic acid; Diacylglycerols (DAG); Glycerophosphocholines (PC); Glycerophosphates (PA) | PE-35:1 ↑ LPC-27:1 ↑ | |
| SM-d18:1/12:0 ↑ | |||||||
| Glutamic acid ↑ | |||||||
| 16 controls | Deoxy sugar ↑ | ||||||
| Arachidonic acid ↑ | |||||||
| DAG ↓ PC ↓ PA ↓ | |||||||
| Pinilla et al. | 2022 | 206 subjects: 142 OSA subjects [apnea-hypopnea index ≥15 events/hour after polysomnography (PSG)] | Serum | UPLC-QTOF-MS | Glycerophospholipid (cardiolipin (CL); Phosphatidylcholine (PC-P (36:4)); Phosphatidylethanolamine (PE)); Sterols (bile acids); Oxylipids; 25-Cinnamoyl vulgaroside; Glycocholic acid; Bilirubin | CL ↑ PC-P (36:4) ↑ PE ↑ Sterols (bile acids) ↑ Oxylipids ↑ | The metabolites were mainly involved in glycerophospholipid metabolism, primary bile acid biosynthesis, linoleic acid metabolism, α-linolenic acid metabolism and glycosylphosphatidylinositol acid metabolism |
| Effect of CPAP treatment on the circulating profile of OSA patients: | |||||||
| 25-Cinnamoyl vulgaroside ↑ Glycocholic acid ↑ Bilirubin ↑ | |||||||
| Xu et al. | 2018 | 30 pediatric subjects with OSA compared to a control group | Urine | UPLC-Q-TOF-MS coupled with GC-TOF-MS | Carbohydrates; Amino acid; Metabolites of microbial origin; Vitamins; Citrulline; Ornithine; 7-Methylguanine; Adenine; Uridine; 3,4,5-Trihydroxypentanoic acid; Quinic acid; Glycerol phosphate; Butanoate; Glucuronic acid; 2-Methylacetoacetic acid; 3-Methyl-2-pentenedioic acid; 3-pyridylacetic acid; Methylcitric acid; Oxalic acid | Increase in biomarker candidates in pediatric OSA patients ↑ | The metabolites were involved in amino acid metabolism, carbohydrate metabolism, microbial metabolism, vitamin metabolism, ornithine cycle, nucleic acid metabolism, fatty acid metabolism, butanoate metabolism, and bilirubin metabolism |
| Noise trauma | |||||||
| Ji et al. | 2019 | CBA/J mice (aged 8–12 weeks) subject to exposure to octave band noise (8–16 kHz) | Tissue | UHPLC-QqQ coupled with LC-MS/MS | Nucleotides; Cofactors; Carbohydrates; Glutamate; Amino acids; Cytosine; N-methyl-L-glutamate; L-methionine; L-arginine | Nucleotides ↑ Cofactors ↑ Carbohydrates ↑ Glutamate ↑ | The metabolites were involved in metabolism of alanine, aspartate, purine, glutamine and glutamate, and the metabolism of phenylalanine, tyrosine and tryptophan |
| Amino acids ↓ | |||||||
| Change in metabolites with respect to the intensity and duration of noise exposure: | |||||||
| Cytosine ↑ N-methyl-L-glutamate ↑ | |||||||
| L-methionine ↓ | |||||||
| L-arginine ↓ | |||||||
| Miao et al. | 2021 | 62 NIHL patients | Plasma | UHPLC-Q-TOF MS | Homodeoxycholic acid; Quinolacetic acid; 3,4-dihydroxymandelic acid; PE (15: 0/20: 2 (11Z, 14Z)); PC (15: 0/18: 1 (11Z)); PI (O-20: 0/18: 0) | Homodeoxycholic acid ↑ Quinolacetic acid ↑ 3,4-dihydroxymandelic acid ↑ | Autophagy pathway was particularly involved in patients with NIHL |
| 62 Controls | PE ↓ PC ↓ PI ↓ | ||||||
A brief summary of the harmonization steps.
| Data preprocessing | Data analysis | Results |
|---|---|---|
| • Quality control | • Discriminant analysis | • Metabolite annotation |
| • Metabolite centering and scaling | • Correlation analysis | • Minimum reporting requirements |
| • Metabolite transformation | • Pathway analysis | • Meta-data |
| • Calculation of biomarker performance | ||
| • Multiple testing correction | ||
| • Validation of results |